NMDA receptor antagonism with novel indolyl, 2-(1,1-Dimethyl-1,3-dihydro-benzo[e]indol-2-ylidene)-malonaldehyde, reduces seizures duration in a rat model of epilepsy

• Main Authors: Rothan, H.A., Amini, E., Faraj, F.L., Golpich, M., Teoh, T.C., Gholami, K., Yusof, R.
• Format: Article
• Language: English
• Published: Nature Publishing Group 2017
• Subjects: Q Science (General); R Medicine
• Online Access: http://eprints.um.edu.my/19038/1/NMDA_receptor_antagonism_with_novel_indolyl.pdf; http://eprints.um.edu.my/19038/; http://dx.doi.org/10.1038/srep45540

N-methyl-D-aspartate receptors (NMDAR) play a central role in epileptogensis and NMDAR antagonists have been shown to have antiepileptic effects in animals and humans. Despite significant progress in the development of antiepileptic therapies over the previous 3 decades, a need still exists for novel therapies. We screened an in-house library of small molecules targeting the NMDA receptor. A novel indolyl compound, 2-(1,1-Dimethyl-1,3-dihydro-benzo[e]indol-2-ylidene)-malonaldehyde, (DDBM) showed the best binding with the NMDA receptor and computational docking data showed that DDBM antagonised the binding sites of the NMDA receptor at lower docking energies compared to other molecules. Using a rat electroconvulsive shock (ECS) model of epilepsy we showed that DDBM decreased seizure duration and improved the histological outcomes. Our data show for the first time that indolyls like DDBM have robust anticonvulsive activity and have the potential to be developed as novel anticonvulsants.